Rachel Narozniak, MA

Articles

OCM Participants Consider Costs of 2-Sided Risk

November 25th 2019

After 3 years of struggling to meet targets for improved care quality and cost efficiency, many of the 175 practices that have remained in the Oncology Care Model of the Centers for Medicare & Medicaid Services have a decision to make: Assume a share of the downside risk for failure to meet financial targets or exit the OCM by December 3.

Prostate Cancer Consensus Panel to Script Testing Guidelines for Inherited Disease

November 19th 2019

Although the oncology community has made many advancements in understanding the role of germline mutations in prostate cancer, a pressing need exists for clarity in determining which genes should be included in testing panels and what steps should be taken to counsel patients at risk and their families.

Novel Therapy May Boost Efficacy of Chemotherapy Backbone in mCRC

November 18th 2019

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Wearable Health Tech Faces Hurdles in Oncology

November 15th 2019

Although use of wearable mobile health monitors has soared in other fields of healthcare, adoption of these electronic devices has lagged in oncology.

Investigators Link Novel Biomarker to Therapy in DLBCL Trial

November 12th 2019

Investigators are exploring the novel genetic biomarker DGM1 as a potential predictor of benefit from the experimental agent enzastaurin in treatment-naïve patients with high-risk diffuse large B-cell lymphoma.

Plasma NGS Demonstrating Practice-Changing Potential in NSCLC

November 12th 2019

Plasma genotyping is the next big thing in non–small cell lung cancer, and it's already impacting clinical practice.

Role of Neoadjuvant Immunotherapy Being Refined in Resectable NSCLC

November 10th 2019

Neoadjuvant immunotherapy can offer promise to patients with resectable non–small cell lung cancer, but further investigation is required for optimal use, Tina Cascone, MD, PhD, said in a presentation during the 14th Annual New York Lung Cancers Symposium®.

SITC Introduces Guidelines for Anti–PD-1 Therapy in HNSCC

October 31st 2019

Based on strong findings for efficacy and safety, as well as FDA approvals, the Society for Immunotherapy of Cancer has issued the first guidelines for the use of immunotherapy agents in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Early Adjuvant Chemotherapy Dose Reductions Correlate With Poorer Survival in Breast Cancer

October 31st 2019

Early dose reductions in a common adjuvant chemotherapy regimen were associated with inferior survival outcomes in a retrospective study of women with intermediate- to high-risk breast cancer.

Immunotherapies, Novel Agents Push Envelope in SCLC

October 23rd 2019

With several agents in development, small cell lung cancer, which constitutes up to 15% of lung cancers, is the focus of increased clinical investigation that may make further treatment inroads.

Investigators Aim at B-Cell Malignancies Using Targeted Radiopharmaceutical

October 16th 2019

In the phase II CLOVER-1 trial, investigators are evaluating whether CLR 131 will be an effective option for patients with difficult-to-treat relapsed or refractory B-cell lymphomas.

IBM Seeks Niche for Watson for Oncology

October 15th 2019

The artificial intelligence system that IBM designed for oncology has demonstrated clinical utility in recent studies, generating excitement that the technology may have a role as a decision support tool.

Innovative Center Focuses on Phase I Trials

October 15th 2019

A partnership between a healthcare system in Morristown, New Jersey, and a genomics research institute in Phoenix, Arizona, has led to the opening of a center dedicated to offering phase I cancer trials in community settings and improving access for patients with limited coverage.

ATOMIC Looks at Immunotherapy in Early-Stage dMMR Colon Cancer

October 7th 2019

Investigators are seeking to determine whether immunotherapy that has been effective in metastatic colon cancers with deficient DNA mismatch repair can be applied to earlier-stage disease, specifically, nonmetastatic stage III colon cancer.

New ASCO System Confronts Lack of EHR Interoperability

October 3rd 2019

With the recent launch of a free, open-source system for standardizing the electronic storage of patient records, the American Society of Clinical Oncology hopes to improve information flow across electronic health record platforms and curtail the harms of information blocking by private aggregators and vendors of patient information.

Medical Partners Open Phase I Trial Center to Improve Access, Novel Drug Development

September 27th 2019

Atlantic Health System of Morristown New Jersey and Translational Genomics Research Institute of Arizona have opened a center dedicated to phase I clinical trials in cancer and improving access for patients with limited coverage.

Workplace Accommodations Would Ease the Burden for Patients With Cancer

September 26th 2019

Women with breast cancer who have lower incomes and are members of minority populations are less likely to return to work following surgery and chemotherapy, and oncologists need to help them obtain workplace accommodations to ease their return to employment.

Immune Checkpoint Inhibitors Correlate With Specific Neurologic Events

September 23rd 2019

Use of immune checkpoint inhibitors was clearly associated with higher incidences of specific neurologic toxicities in a broad-based retrospective pharmacovigilance study, and clinicians need to monitor for these immune-related adverse events when using these agents.

Lasofoxifene Explored in ESR1-Mutated ER+/HER2- Breast Cancer

September 12th 2019

Investigators are exploring whether lasofoxifene can stop disease progression in women with advanced or metastatic estrogen receptor (ER)–positive, HER2-negative breast cancer with an ESR1 mutation in the multicenter phase II ELAINE trial (NCT03781063).

Molecular Testing Enhances Decision-Making Process in Thyroid Cancer of Indeterminate Malignancy

September 7th 2019

In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration cytology to determine the best course of treatment based on cytopathological result.